Boston, US, and Rolle, Switzerland, September 7, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care..

2024年9月7日，美国波士顿和瑞士罗尔讯——SOPHiA GENETICS（纳斯达克：SOPH）是一家云计算的本土医疗保健技术公司，也是数据驱动医学的全球领导者，今天宣布该公司将加入欧洲液体活检协会（ELBS），这是一个由学术界和工业界合作伙伴组成的享有盛誉的网络，其共同目标是将液体活检测试作为常规护理标准的一部分。。

SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA).

SOPHiA GENETICS提供了一套全面的液体活检应用程序，有助于推进肿瘤学研究和肿瘤突变分析。液体活检检测通过从血浆中分离无细胞DNA（cfDNA）提供了实体瘤检测的替代方法，这可能会发现循环肿瘤DNA（ctDNA）。

This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. .

这种非侵入性测试可以进行癌症基因组分析和疾病监测。在许多情况下，由于组织材料不足，获得的组织质量低或程序的侵袭性，肿瘤组织的基因组测试可能不可行，这揭示了关键的见解。。

The ELBS primarily focuses on liquid biopsy testing for cancer, which aligns with the work that SOPHiA GENETICS has done to increase access to this sophisticated testing. SOPHiA GENETICS decentralized MSK-ACCESS®, the highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK), so customers in Europe and worldwide have access to a best-in-class liquid biopsy solution..

ELBS主要关注癌症的液体活检检测，这与SOPHiA GENETICS为增加这种复杂检测的机会所做的工作相一致。SOPHiA GENETICS分散了MSK-ACCESS®，这是由纪念斯隆·凯特琳癌症中心（MSK）开发的经过高度验证的ctDNA检测方法，因此欧洲和全球的客户都可以获得一流的液体活检解决方案。。

“ELBS facilitates scientific exchange, clinical studies, and networking between leading experts, and we are thrilled to have SOPHiA GENETICS bring their global expertise and insights to our dynamic network of partners as we advance the field of liquid biopsy,” said Dr. Klaus Pantel, Founder and Chairman of the ELBS..

。。

“We are impressed by the expansive community that the ELBS has created and are looking forward to collaborating with the ELBS to move this groundbreaking field forward to further widespread adoption and reimbursement for liquid biopsy testing,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS.  “We believe that our participation will bring best-in-class technology and key learnings from our global community to complement and enhance the work of the ELBS moving forward.”.

索菲亚遗传学（SOPHiA GENETICS）欧洲、中东和非洲（EMEA）董事总经理凯文·普莱尔特（KevinPuylaert）表示：“ELBS创建的广泛社区给我们留下了深刻印象，我们期待着与ELBS合作，将这一开创性的领域向前推进，以进一步广泛采用和报销液体活检检测。”。“我们相信，我们的参与将为全球社区带来一流的技术和关键知识，以补充和加强ELBS的工作。”。

The ELBS network currently consists of more than 87 member institutions including academic institutions and university hospitals, as well as industry partners spread across biotech, device manufacturers, diagnostic companies, standard providers and pharmaceutical companies. Several members of the society, such as IUCT-Oncopole, work with SOPHiA GENETICS for liquid biopsy testing..

ELBS网络目前由87多个成员机构组成，包括学术机构和大学医院，以及遍布生物技术、设备制造商、诊断公司、标准供应商和制药公司的行业合作伙伴。该协会的一些成员，例如IUCT Oncopole，与SOPHiA GENETICS合作进行液体活检测试。。

“We are pleased to welcome SOPHiA GENETICS to the European Liquid Biopsy Society. As the first laboratory in France and first European Liquid Biopsy member to adopt the MSK-ACCESS® powered with SOPHiA DDM™ application, we have experienced firsthand the technical expertise of the team at SOPHiA GENETICS combined with the analytical power of the SOPHiA DDM™ Platform to produce high-quality, meaningful insights for our teams.

“我们很高兴欢迎SOPHiA GENETICS加入欧洲液体活检协会。作为法国第一个实验室，也是第一个采用由SOPHiA DDM™应用程序提供动力的MSK-ACCESS®的欧洲液体活检成员，我们亲身体验了SOPHiA GENETICS团队的技术专长，并结合了SOPHiA DDM™平台的分析能力，为我们的团队提供了高质量、有意义的见解。

We are looking forward to continuing to further the field of liquid biopsy while serving our patients alongside the SOPHiA GENETICS team,” said a representative of the biology laboratory of medical oncology from IUCT-Oncopole in Toulouse..

图卢兹IUCT Oncopole医学肿瘤学生物学实验室的一位代表说：“我们期待着继续推进液体活检领域，同时与SOPHiA遗传学团队一起为我们的患者提供服务。”。。

###

###

About European Liquid Biopsy Society

关于欧洲液体活检协会

The European Liquid Biopsy Society” Network was developed from the EU IMI “CANCER-ID” project (2015-2019) to further strengthen the field of Liquid Biopsy. The ELBS combines domestic and international orientation and promotes exchange between academic, industrial and clinical sectors as well as the health care system..

欧洲液体活检协会”网络是由欧盟IMI“癌症ID”项目（2015-2019）开发的，以进一步加强液体活检领域。ELBS结合了国内和国际导向，促进了学术、工业和临床部门以及医疗保健系统之间的交流。。

The network is further intended to promote the development of standardized guidelines and training in the field of “Liquid Biopsy” for physicians and researchers in related disciplines. The network, including third parties, also launches public relations campaigns on the subject of “Liquid Biopsy”, for example by sponsoring symposiums, presentations and press releases..

该网络还旨在促进为相关学科的医生和研究人员制定“液体活检”领域的标准化指南和培训。。。

About SOPHiA GENETICS

关于SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. .

SOPHiA GENETICS（Nasdaq:SOPH）是一家云本地医疗保健技术公司，其使命是通过使用人工智能来释放见解，为全球患者提供世界一流的护理，从而扩大对数据驱动医学的访问。它是SOPHiA DDM™的创建者，该平台可分析复杂的基因组和多模式数据，并为医院，实验室和生物制药机构的广泛全球网络生成实时可行的见解。有关更多信息，请访问SOPHiAGENETICS。COM并通过LinkedIn与我们联系。。

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.

除非另有说明，否则SOPHiA GENETICS产品仅供研究使用，不用于诊断程序。本新闻稿中的信息是关于不同国家可能提供或不提供的产品，如果适用，可能已经或可能尚未获得政府监管机构对不同使用适应症的批准或市场许可。

Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. .

请联系support@sophiagenetics.com获取您居住国家的适当产品信息。。

SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements.

SOPHiA GENETICS前瞻性声明：本新闻稿包含构成前瞻性声明的声明。除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括关于我们未来经营成果和财务状况、经营战略、产品和技术以及未来经营管理计划和目标的声明。

Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S.

前瞻性陈述基于管理层的信念和假设以及管理层目前可获得的信息。此类报表存在风险和不确定性，由于各种因素，包括我们向美国提交的文件中所述的因素，实际结果可能与前瞻性报表中明示或暗示的结果存在重大差异。

Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law.

证券交易委员会。不能保证将来会取得这样的结果。本新闻稿中包含的此类前瞻性声明仅在本新闻稿发布之日有效。除非适用法律要求，否则我们明确否认有义务或承诺更新本新闻稿中包含的前瞻性声明，以反映我们预期的任何变化或此类声明所依据的事件、条件或情况的任何变化。

No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements..

对于任何此类前瞻性陈述的准确性，不作任何陈述或保证（明示或暗示）。。

Media Contact: Kelly Katapodismedia@sophiagenetics.com

Katapodismedia@sophiagenetics.com